ASCO 2023 | PD-1 and GITR inhibition with radiotherapy in patients with rGBM

Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, describes the trial design of a Phase II trial (NCT04225039) of retifanlimab, INCAGN01876 (GITR agonist), and fractionated stereotactic radiotherapy (FSRT) in patients with recurrent glioblastoma (rGBM). There were two main arms, one with patients who do not need surgical resection and another with patients who received surgical resection. The latter arm was further subdivided into patients who received radiotherapy and another who only received immune checkpoint inhibition. Overall response rate (ORR) was the primary endpoint. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.